Nurix Therapeutics
Nurix Therapeutics
NRIX
NASDAQ
13.77
USD
4.40%
About
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases.
It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies.
NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 487.0K |
| Three Month Average Volume | 18.7M |
| High Low | |
| Fifty-Two Week High | 26.1225 USD |
| Fifty-Two Week Low | 4.22 USD |
| Fifty-Two Week High Date | 26 Aug 2024 |
| Fifty-Two Week Low Date | 26 Oct 2023 |
| Price and Volume | |
| Current Price | 25.2 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 14.79% |
| Thirteen Week Relative Price Change | 49.49% |
| Twenty-Six Week Relative Price Change | 69.02% |
| Fifty-Two Week Relative Price Change | 136.60% |
| Year-to-Date Relative Price Change | 106.20% |
| Price Change | |
| One Day Price Change | 0.80% |
| Thirteen Week Price Change | 60.00% |
| Twenty-Six Week Price Change | 85.84% |
| Five Day Price Change | 4.91% |
| Fifty-Two Week Price Change | 196.47% |
| Year-to-Date Price Change | 144.19% |
| Month-to-Date Price Change | 15.17% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.11533 USD |
| Book Value Per Share (Most Recent Quarter) | 5.75999 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.11533 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 5.75999 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.01925 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.41682 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.10105 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.64913 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.91772 USD |
| Normalized (Last Fiscal Year) | -2.64913 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.64913 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.91772 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.64913 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.91772 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.90962 USD |
| Cash Per Share (Most Recent Quarter) | 6.88569 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.51049 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.77002 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.87266 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -184 |
| Cash Flow Revenue (Trailing Twelve Months) | -170 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -264.55% |
| Pretax Margin (Last Fiscal Year) | -186.98% |
| Pretax Margin (5 Year) | -271.03% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -201.41% |
| Operating Margin (Trailing Twelve Months) | -287.47% |
| Operating Margin (5 Year) | -280.00% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -186.98% |
| Net Profit Margin (Trailing Twelve Months) | -264.84% |
| Net Profit Margin (5 Year) | -260.65% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 32.77% |
| Tangible Book Value (5 Year) | 77.60% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -60.58% |
| Revenue Growth (3 Year) | 15.50% |
| Revenue Change (Trailing Twelve Months) | 2.25% |
| Revenue Per Share Growth | -15.51% |
| Revenue Growth (5 Year) | 62.87% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 39.42% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -59.61% |
| EPS Change (Trailing Twelve Months) | 1.64% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -443,139,000 |
| Net Debt (Last Fiscal Year) | -287,908,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 21 |
| Price to Sales (Trailing Twelve Months) | 26 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 6 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -89,766,000 |
| Free Cash Flow (Trailing Twelve Months) | -105,965,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -37.27% |
| Return on Assets (Trailing Twelve Months) | -38.30% |
| Return on Assets (5 Year) | -33.01% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -57.10% |
| Return on Equity (Trailing Twelve Months) | -52.33% |
| Return on Equity (5 Year) | -52.73% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -46.83% |
| Return on Investment (Trailing Twelve Months) | -46.57% |
| Return on Investment (5 Year) | -39.66% |